Cell-Based Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cell-Based Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The cell-based assay market is expected to register a CAGR of 6.52% over the forecast period.

COVID-19 had a significant impact on the growth of the market. the cell-based assays are useful to discover inhibitors of the COVID-19 virus infection. According to the article titled "A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependant RNA polymerase" published in June 2021 cell-based assay is used to evaluate the efficacy of nucleotide analog compounds against SARS-CoV-2 RdRp and the assay is used to assess their tolerance to viral exoribonuclease-mediated proofreading. Thus COVID-19 propelled the demand for cell-based assays during the pandemic period.

The cell-based assay market is expected to show rapid growth due to the rising prevalence of chronic diseases and lifestyle disorders, increasing investments in R&D for drug discovery, and the rise in technological advancements in cell-based methodologies.

The rising prevalence of chronic diseases and lifestyle disorders, such as cancer, cardiovascular, diabetes, and neurological disorders is one of the primary factors fueling the market growth. The report published by International Agency for Research on Cancer (IARC) in December 2020 that the global cancer burden has risen to 19.3 million cases. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases. And thus, due to the high incidence of cancer around the world, the demand for effective therapy or treatment is increasing which is expected to drive the growth of the cell-based assay market during the forecast period.

According to the data published by the European Heart network in 2021 reported that in the European Union more than 60 million people live with cardiovascular disease and close to 13 million new cases of cardiovascular diseases are diagnosed every year. Thus, the rise in chronic diseases leads to demand growth for cell-based assays for new drug discoveries, making it a vital factor for market growth. In addition, the demand for cell-based assays has increased significantly owing to a surge in cell-based applications in drug discovery and the rise in technological advancements in cell-based assay methodologies.

Additionally, innovative product launches by key market players are expected to drive the growth of the market. For instance, in May 2021, Viskol launched DILI 3D cell culture assay services using corning-qualified 3D PHH spheroid assay-ready plates.

Thus the above-mentioned factors are expected to drive the growth of the market during the forecast period. However, high maintenance and operational costs are expected to hinder the growth of the market.

Key Market TrendsDrug Discovery is Expected to be the Fast Growing Segment in the Cell-Based Assay Market Over the Forecast Period

The drug discovery segment is anticipated to show high growth in the market and this growth can be attributed to the increase in the R&D investment by biopharmaceutical companies. In addition, the rise in the prevalence of chronic diseases, such as cancer, osteoarthritis, cardiovascular diseases, and diabetes, is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market. According to the article titled " 2022 Funding forecast: strong R&D growth with clouds on the horizon" published in April 2022 the United States federal government is expected to invest USD 181.4 billion in research and development in 2022. Such investment in research and development are expected to contribute to the growth of the studied segment over the forecast period.

In cell-based assays, functional cells are used as diagnostic tools in research for new drugs that help in drug discovery. The increasing market players' activities such as partnerships and collaborations for drug discovery are expected to drive the growth of the studied segment during the forecast period. For instance, in February 2021, Selvitalaunched the cell-based phenotypic assay platform for drug discovery. The platform will be used to test new compounds with therapeutic potential in multiple areas.

Furthermore, In June 2020, PhenoVista Biosciences collaborated with Olympus to deliver 3D cell-based assay services for drug discovery.

Thus the above-mentioned factors are expected to drive the demand for the growth of the studied segment during the forecast period.

North America is Expected to Dominate the Cell-Based Assay Market During the Forecast Period

North America is the dominating region across the world in terms of market share owing to the well-established healthcare sector along with the high adoption of cell-based assays. In the United States, the prevalence of chronic diseases, such as cancer, osteoarthritis, and diabetes, is increasing which is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market.For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.

Similarly, the American Heart Association in January 2022 mentioned that approximately every 40 seconds, someone in the United States will have a myocardial infarction. Such a high frequency of chronic diseases among the United States population is expected to drive the growth of the market during the forecast period.

Additionally, the market players activities for the development of cell based assays is expected to growth of the market in this region. For instance , in March 2022, Promega Corporation Collaborated with the FUJIFILM cellular dynamics to create novel assays to observe cellular biology in a system that better reflects how cells behave in the human body.

Thus the above-mentioned factors are expected to drive the growth of the market in this region during the forecast period.

Competitive Landscape

The cell-based assay market is moderately fragmented in nature due to the presence of several companies operating globally as well as regionally. The key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., and Promega Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.